Clinical Trial Update: Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating carboplatin, Abraxane, and bevacizumab in previously untreated advanced non-small cell lung cancer completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-12-12